AU2001259056A1 - Method for selectively inhibiting ghrelin action - Google Patents

Method for selectively inhibiting ghrelin action

Info

Publication number
AU2001259056A1
AU2001259056A1 AU2001259056A AU5905601A AU2001259056A1 AU 2001259056 A1 AU2001259056 A1 AU 2001259056A1 AU 2001259056 A AU2001259056 A AU 2001259056A AU 5905601 A AU5905601 A AU 5905601A AU 2001259056 A1 AU2001259056 A1 AU 2001259056A1
Authority
AU
Australia
Prior art keywords
selectively inhibiting
ghrelin action
inhibiting ghrelin
action
selectively
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259056A
Inventor
Henry Uhlman Bryant
Mark Louis Heiman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001259056A1 publication Critical patent/AU2001259056A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
AU2001259056A 2000-05-17 2001-05-07 Method for selectively inhibiting ghrelin action Abandoned AU2001259056A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20489700P 2000-05-17 2000-05-17
US60204897 2000-05-17
PCT/US2001/011752 WO2001087335A2 (en) 2000-05-17 2001-05-07 Method for selectively inhibiting ghrelin action

Publications (1)

Publication Number Publication Date
AU2001259056A1 true AU2001259056A1 (en) 2001-11-26

Family

ID=22759933

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259056A Abandoned AU2001259056A1 (en) 2000-05-17 2001-05-07 Method for selectively inhibiting ghrelin action

Country Status (3)

Country Link
EP (1) EP1286697A2 (en)
AU (1) AU2001259056A1 (en)
WO (1) WO2001087335A2 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151040A1 (en) 2000-02-18 2002-10-17 Matthew O' Keefe Apparatus and methods for parallel processing of microvolume liquid reactions
US20100261159A1 (en) 2000-10-10 2010-10-14 Robert Hess Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
WO2002030561A2 (en) 2000-10-10 2002-04-18 Biotrove, Inc. Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
JP4493913B2 (en) * 2001-01-31 2010-06-30 中外製薬株式会社 Undernutrition Symptom Treatment Agent
CA2446857A1 (en) * 2001-05-10 2002-11-14 Queensland University Of Technology Reproductive cancer diagnosis and therapy
DE60230818D1 (en) 2001-09-24 2009-02-26 Imp Innovations Ltd PYY3-36 FOR REDUCING OR PREVENTING GREASE LUBRICITY
EP1455814B1 (en) 2001-12-18 2012-04-04 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin for use in the treatment of insulin resistance
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
BR0306685A (en) * 2002-05-21 2005-04-26 Daiichi Suntory Pharma Co Ltd Pharmaceutical composition containing ghrelin
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
MXPA05000160A (en) * 2002-07-05 2006-02-28 Chugai Pharmaceutical Co Ltd Remedy for diabetes.
AU2003251681A1 (en) 2002-08-01 2004-02-23 Noxxon Pharma Ag Ghrelin binding nucleic acids
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
EP1539232A1 (en) * 2002-09-12 2005-06-15 Pharmexa A/S Immunization against autologous ghrelin
WO2004056869A1 (en) * 2002-12-20 2004-07-08 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
EP1608952B1 (en) 2002-12-20 2016-08-10 Life Technologies Corporation Assay apparatus and method using microfluidic arrays
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004084943A1 (en) * 2003-03-19 2004-10-07 Beth Israel Deaconess Medical Center, Inc Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
EP1670827A2 (en) * 2003-09-05 2006-06-21 Eli Lilly And Company Anti-ghrelin antibodies
US7825090B2 (en) 2003-10-24 2010-11-02 Alizé Pharma SAS Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance
US7252665B2 (en) 2003-10-31 2007-08-07 Medtronic, Inc Ablation of stomach lining to reduce stomach acid secretion
US7282050B2 (en) 2003-10-31 2007-10-16 Medtronic, Inc. Ablation of exterior of stomach to treat obesity
KR20060125743A (en) * 2003-11-10 2006-12-06 녹손 파르마 아게 Nucleic acids specifically binding bioactive ghrelin
CA2559171A1 (en) 2004-03-12 2005-09-29 Biotrove, Inc. Nanoliter array loading
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
WO2005097831A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of isolated binding members capable of binding specifically to secretagogues
WO2005097830A2 (en) * 2004-04-07 2005-10-20 Aditech Pharma Ab Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
JP2007537434A (en) * 2004-05-14 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ Functional GHS-R antagonist
GB0411014D0 (en) * 2004-05-18 2004-06-23 Haptogen Ltd Methods for the control treatment and management of obesity
CA2569235A1 (en) * 2004-07-14 2006-02-23 Eli Lilly And Company Anti-ghrelin antibodies
US20060105453A1 (en) 2004-09-09 2006-05-18 Brenan Colin J Coating process for microfluidic sample arrays
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
WO2006091381A1 (en) * 2005-02-23 2006-08-31 Eli Lilly And Company Humanized anti-ghrelin antibodies
AR052741A1 (en) 2005-04-08 2007-03-28 Noxxon Pharma Ag NUCLEIC ACIDS FROM UNION TO GHRELIN
US7736392B2 (en) 2005-04-28 2010-06-15 Medtronic, Inc. Bulking of upper esophageal sphincter for treatment of obesity
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
BRPI0616463A2 (en) 2005-09-29 2011-06-21 Merck & Co Inc compound, pharmaceutical composition, and use of a compound
WO2007092023A1 (en) 2006-02-11 2007-08-16 Boston Biomedical Research Institute Compositions and methods for binding or inactivating ghrelin
US20110143992A1 (en) * 2006-02-13 2011-06-16 Dennis Taub Methods and Compositions Related to GHS-R Antagonists
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
US8318664B2 (en) 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
EP2152297B1 (en) 2007-05-31 2015-04-29 Alizé Pharma SAS Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
JP2011522828A (en) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
US8476408B2 (en) 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
MX2011004258A (en) 2008-10-22 2011-06-01 Merck Sharp & Dohme Novel cyclic benzimidazole derivatives useful anti-diabetic agents.
KR101320245B1 (en) 2008-10-30 2013-10-30 머크 샤프 앤드 돔 코포레이션 Isonicotinamide orexin receptor antagonists
JP5557845B2 (en) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション Novel cyclic benzimidazole derivatives useful as antidiabetic agents
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US20110105389A1 (en) 2009-10-30 2011-05-05 Hoveyda Hamid R Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR20150075120A (en) 2011-02-25 2015-07-02 머크 샤프 앤드 돔 코포레이션 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
PL2790721T3 (en) 2011-12-15 2019-05-31 Millendo Therapeutics Sas Fragments of unacylated ghrelin for use in the treatment of prader-willi syndrome
RU2015106909A (en) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. ANTI-DIABETIC TRICYCLIC COMPOUNDS
KR20150118158A (en) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2926685A1 (en) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
CN109952292A (en) 2016-10-14 2019-06-28 Tes制药有限责任公司 Pantonine-carboxyl muconic acid semialdehyde removes the inhibitor of carboxylic acid
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
JP2022507805A (en) 2018-11-20 2022-01-18 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ α-Amino-β-carboxymuconic acid semialdehyde decarboxylase inhibitor
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CA3189908A1 (en) 2020-08-18 2022-02-24 Stephane L. Bogen Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021730A1 (en) * 1995-12-13 1997-06-19 Merck & Co., Inc. Growth hormone secretagogue receptor family
JP2002520011A (en) * 1998-07-13 2002-07-09 メルク・アンド・カンパニー・インコーポレーテッド Growth hormone secretagogue-related receptors and nucleic acids
JP2002522058A (en) * 1998-08-10 2002-07-23 メルク・アンド・カンパニー・インコーポレーテッド Canine growth hormone secretagogue receptor

Also Published As

Publication number Publication date
WO2001087335A2 (en) 2001-11-22
WO2001087335A3 (en) 2002-05-16
EP1286697A2 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
AU2001259056A1 (en) Method for selectively inhibiting ghrelin action
GB0016459D0 (en) Method
IL156476A0 (en) Match control method
AU2002210881A1 (en) Transdermal method
AU7090201A (en) Method
AU2001234730A1 (en) Method for inhibiting complement activation
GB0009353D0 (en) Method
AU2002214487A1 (en) Method for inducing apoptiosis
AU2001237530A1 (en) Method
GB0005867D0 (en) Method
AU2001241636A1 (en) Halotherapy method
AU2002234589A1 (en) Method for controlling id cards
AU2002220757A1 (en) Method for obtaining azaerythromycin
GB0007873D0 (en) Method
GB0018039D0 (en) Method
AU2002228975A1 (en) Method
AU2001235770A1 (en) Method
GB0013260D0 (en) Method
GB0007872D0 (en) Method
AU2001226002A1 (en) Method for extracting bisbenzylisoquinolines
AU2002210790A1 (en) Method for making micromolds
AU1079002A (en) Method for making micromolds
AU2002214425A1 (en) Method for stopping landslides
GB0006590D0 (en) Method
GB0007564D0 (en) Method